T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer
Year: 2022
Type: article
Abstract: Aim: Investigate the relationship between response to pembrolizumab and expression of the 18-gene T cell-inflamed gene expression profile (TcellinfGEP) or PD-L1 combined positive score (CPS) in esophageal cancer. Materials & methods: This analysis included heavily pretreated patients with advanced/metastatic esophageal/gastroesophageal junction adenocarcinoma or squamous cell carcinoma who received pembrolizumab in the single-arm, phase II study KEYNOTE-180. PD-L1 CPS was evaluated with PD-L1 IHC 22C3 pharmDx. Results: In patients with squamous cell carcinoma, trends toward enrichment for responders were observed for patients with PD-L1 CPS ≥10 tumors. In patients with adenocarcinoma, a trend was observed for TcellinfGEP but not for PD-L1. Conclusion: TcellinfGEP and PD-L1 CPS may enrich for responders to pembrolizumab in patients with esophageal cancer. Clinical Trial Registration: NCT02559687 (ClinicalTrials.gov)
Source: Future Oncology
Authors: Manish A Shah, Takashi Kojima, Daniel Hochhauser, Peter Enzinger, Judith Raimbourg, Antoine Hollebecque, Florian Lordick, Sung-Bae Kim, Masahiro Tajika, Albert Craig Lockhart, Hendrick-Tobias Arkenau, Farid El-Hajbi, Mukul Gupta, Per Pfeiffer, Pooja Bhagia, Zhu Alexander Cao, Jared Lunceford, Shailaja Suryawanshi, Mark Ayers, Matthew J Marton, Ken Kato
Institutions: NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill Cornell Medical Center, National Cancer Center Hospital East, University College London Hospitals NHS Foundation Trust, Dana-Farber Cancer Institute, Institut de Cancérologie de l'Ouest, Institut Gustave Roussy, Fondation Gustave Roussy, University Hospital Leipzig, Leipzig University, Asan Medical Center, University of Ulsan, Aichi Cancer Center, Aichi Cancer Center Hospital, University of Miami, Sarah Cannon Research Institute, University College London, Centre Oscar Lambret, Sansum Medical Clinic, Odense University Hospital, Merck & Co., Inc., Rahway, NJ, USA (United States), National Cancer Center Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4285793328